GSK PLC (GSK) is a Zacks Rank #5 (Strong Sell) after the company beat the Zacks Consensus Estimate when the last reported. The company is in the healthcare space and there has been a lot of press ...

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...

“We really became impressed with what IDRx had achieved,” GSK Chief Commercial Officer Luke Miels told Fierce Biotech in an interview ahead of the J.P. Morgan Healthcare Conference.

Luke Miels, GSK’s chief commercial officer, said: “This acquisition is consistent with our approach of acquiring assets that address validated targets and where there is clear unmet medical ...